Encompass Health Co. (NYSE:EHC) Shares Sold by XTX Topco Ltd

XTX Topco Ltd cut its stake in Encompass Health Co. (NYSE:EHC) by 68.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,006 shares of the company’s stock after selling 13,187 shares during the quarter. XTX Topco Ltd’s holdings in Encompass Health were worth $555,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in EHC. Charles Schwab Investment Management Inc. grew its position in Encompass Health by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company’s stock valued at $59,544,000 after buying an additional 4,345 shares during the period. Central Pacific Bank Trust Division boosted its position in Encompass Health by 15.1% during the fourth quarter. Central Pacific Bank Trust Division now owns 3,195 shares of the company’s stock worth $295,000 after purchasing an additional 418 shares in the last quarter. Merit Financial Group LLC acquired a new stake in Encompass Health in the fourth quarter valued at approximately $374,000. MassMutual Private Wealth & Trust FSB increased its position in shares of Encompass Health by 87.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after buying an additional 137 shares in the last quarter. Finally, US Bancorp DE lifted its position in shares of Encompass Health by 9.6% during the 4th quarter. US Bancorp DE now owns 1,380 shares of the company’s stock valued at $127,000 after buying an additional 121 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Trading Up 0.5 %

Shares of Encompass Health stock opened at $103.53 on Friday. Encompass Health Co. has a fifty-two week low of $79.26 and a fifty-two week high of $104.55. The stock has a 50 day moving average of $99.91 and a 200 day moving average of $98.26. The firm has a market capitalization of $10.43 billion, a price-to-earnings ratio of 23.21, a PEG ratio of 2.31 and a beta of 0.87. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05.

Encompass Health (NYSE:EHC) last announced its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. As a group, research analysts predict that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Tuesday, April 1st were paid a dividend of $0.17 per share. The ex-dividend date of this dividend was Tuesday, April 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.66%. Encompass Health’s dividend payout ratio (DPR) is presently 15.25%.

Insider Activity

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now owns 69,164 shares in the company, valued at $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on EHC shares. KeyCorp increased their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, February 10th. William Blair reiterated an “outperform” rating on shares of Encompass Health in a report on Friday, February 7th. Royal Bank of Canada reissued an “outperform” rating and set a $110.00 target price on shares of Encompass Health in a report on Tuesday, February 11th. Barclays lifted their price target on Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Finally, StockNews.com cut shares of Encompass Health from a “buy” rating to a “hold” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Encompass Health currently has an average rating of “Buy” and an average price target of $107.67.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.